501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Files Patent for
Detection of Molecules in Breath using High-field
asymmetric waveform ion mobility spectrometry (FAIMS)
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- July 6, 2020 -- InvestorsHub NewsWire
-- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”)
developer of the Cannabix Marijuana Breathalyzer
for law enforcement and the workplace, is pleased to report that it has filed a provisional patent
application with the United
States Patent and Trademark Office (USPTO)
entitled, “Apparatus and
Methods for Detection of Molecules”. This provisional patent covers
multiple new inventions and intellectual property (“IP”) related
the development to the Company’s
FAIMS (field asymmetric waveform ion mobility
spectrometry) based marijuana
breathalyzer technology. This new patent application is the
culmination of research and development work conducted by Cannabix
scientists and engineers in the areas of ion mobility spectrometry,
fluid dynamics, and non-volatile molecule sampling, during which
several significant technical challenges have been overcome.
This patent application seeks protection for, among others, novel
methods in asymmetric waveform generation and application and ion
optics design. It is anticipated that additional IP will be
included in the subsequent non-provisional patent filing and that
these techniques can lead to utility in other areas related to
detection of molecules in breath.
Cannabix is using its FAIMS
system to isolate and detect ?9-tetrahydrocannabinol
(“THC”), a non-volatile
compound, in breath. The Cannabix device has been designed and
built in a series of modules that together allow for sample intake,
ionization, ion focusing and direction, filtering and detection –
all done under atmospheric pressure. This modular design
provides the flexibility for the potential detection of other
molecules of interest in breath. In addition, the device has
the ability to couple directly to a mass spectrometer in order to
validate its detector responses.
The Company
reported results of field testing earlier this year such that its
FAIMS device is capable of selectively isolating and detecting THC
from human breath up to 90 min after subjects consumed both
marijuana and nicotine. Further improvements have been made
since then and engineers are well into the next iteration of
design.
“Cannabix has
developed a unique system with several non-obvious features that
have been discovered through our commitment to research and
development and innovation. The breath is composed of both
volatile and non-volatile components --volatile components like
alcohol are relatively easy to detect. The detection of
non-volatile compounds like THC under atmospheric pressure (without
vacuum) in a humid environment is not an easy endeavour and we
believe our work will lead to new types of devices that the
analytical and diagnostic fields have been seeking for breath
analysis, and possibly other applications. Furthermore, this provisional patent should open the door
to several additional patent opportunities.” stated Dr. Raj
Attariwala, Chief Scientific Officer.
About Cannabix
Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing accurate,
durable, portable tools to market to enable detection of
marijuana-impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks
earlier. The devices will also be useful for other practical
applications such as testing employees in the workplace where
impairment by THC can be hazardous.
We seek Safe
Harbor.
On behalf
of the Board of Directors
“Rav
Mlait”
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
information that involves various risks and uncertainties regarding
future events. Such forward-looking information can include without
limitation statements based on current expectations involving a
number of risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company’s plans and objectives to differ materially from
those expressed in the forward-looking information, including: (i)
adverse market conditions; (ii) risks regarding protection of
proprietary technology; (iii) the ability of the Company to
complete financings; (iv) the ability of the Company to develop and
market its future product; and (v) risks regarding government
regulation, managing and maintaining growth, the effect of adverse
publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements
and filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing “patent pending” technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.